DexCom, Inc. (NASDAQ:DXCM) Given Average Recommendation of “Moderate Buy” by Brokerages

DexCom, Inc. (NASDAQ:DXCM) has earned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $82.4167.

DXCM has been the topic of a number of research analyst reports. Sanford C. Bernstein set a $77.00 price target on DexCom in a research note on Friday, May 1st. Wells Fargo & Company lowered their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Benchmark started coverage on DexCom in a research report on Monday, May 11th. They set a “buy” rating and a $77.00 price objective on the stock. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Finally, Barclays reiterated an “underweight” rating and set a $64.00 price objective (down from $67.00) on shares of DexCom in a research report on Monday, May 18th.

DexCom Stock Up 1.9%

DXCM opened at $73.74 on Friday. DexCom has a 1-year low of $54.11 and a 1-year high of $89.98. The stock’s fifty day simple moving average is $64.17 and its 200 day simple moving average is $66.44. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The stock has a market cap of $28.45 billion, a PE ratio of 31.51, a price-to-earnings-growth ratio of 1.20 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the prior year, the business earned $0.32 EPS. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. As a group, research analysts expect that DexCom will post 2.57 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares in the company, valued at $7,010,300.16. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares in the company, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,871 shares of company stock worth $2,306,638 in the last 90 days. Company insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Avidity Partners Management LP acquired a new stake in shares of DexCom during the 1st quarter worth $5,652,000. Glenmede Trust Co. NA grew its holdings in shares of DexCom by 36.7% during the 1st quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company’s stock worth $24,790,000 after purchasing an additional 105,928 shares in the last quarter. Wellington Grp LLC grew its holdings in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of DexCom by 32.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock worth $166,077,000 after purchasing an additional 645,534 shares in the last quarter. Finally, Centaurus Financial Inc. acquired a new stake in shares of DexCom during the 1st quarter worth $943,000. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.